Polynoma is an immuno-oncology company focused on developing a novel vaccine, seviprotimut-L, for the adjuvant treatment of melanoma. This vaccine utilizes a technology based on polyvalent shed antigens derived from proprietary human melanoma cell lines. The process involves growing melanoma cells in bioreactors, where they shed melanoma-associated proteins under optimized conditions. These proteins are then partially purified to concentrate the relevant antigens while minimizing extraneous cellular components. This allogeneic vaccine is designed to be "off-the-shelf," making it accessible for all patients rather than being tailored to individual profiles, as seen in personalized vaccine and cell therapy approaches.

The mechanism of action for seviprotimut-L involves stimulating both humoral and cellular immune responses. The melanoma-associated antigens present in the vaccine are taken up by antigen-presenting cells, such as dendritic cells, which activate the production of antigen-specific cytotoxic T-lymphocytes (CTLs) and generate antibody responses. These CTLs and antibodies target and eliminate tumor cells that express the melanoma-associated antigens on their surfaces, thereby aiming to prevent the recurrence of melanoma in patients who have undergone surgical resection. The efficacy and safety of seviprotimut-L are currently being evaluated in clinical trials, including the pivotal Phase III MAVIS study.

United States

Polynoma LLC is a biotechnology company based out of 11230 Sorrento Valley Rd, San Diego, CA, United States.

Polynoma

Company Details